Kreatin Kinaz Yüksekliğine Tanısal Yaklaşım
Özet
Kreatin kinaz (CK), kas hasarının teşhisinde kullanılan kritik bir enzimdir ve yüksekliği nöromüsküler hastalıklardan metabolik bozukluklara kadar geniş bir yelpazeyi işaret edebilir. Tanısal süreç, hastanın semptomatik olup olmadığının belirlenmesiyle başlar; egzersiz, enfeksiyon veya ilaç kullanımı gibi geçici nedenlerin ekarte edilmesi temel esastır. Fizik muayene ve ayrıntılı öykü, ayırıcı tanıda yol göstericidir. Eğer CK yüksekliği devam ediyorsa, daha ileri tetkikler ve spesifik nöromüsküler hastalıklar değerlendirilmelidir.
Creatine kinase (CK) serves as a critical enzyme marker for identifying muscle damage, with elevations indicating conditions ranging from neuromuscular diseases to metabolic disorders. The diagnostic approach begins by determining if the patient is symptomatic and ruling out transient causes such as intense exercise, infections, or medication effects. A thorough physical examination and detailed patient history are essential for narrowing the differential diagnosis. Persistent CK elevation requires further investigation, including targeted testing for specific neuromuscular pathologies.
Referanslar
Bohlmeyer TJ, Wu AH, Perryman MB. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am. 1994 Nov;20:845-856.
Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem. 1985 Jul; 54:831-862.
Blum HE, Deus B, Gerok W. Mitochondrial creatine kinase from human heart muscle: purification and characterization of the crystallized isoenzyme. J Biochem. 1983 Oct;94:1247-1257.
Katiriji B, Al Jaberi MM. Creatine kinase revisited. J Clin Neuromuscul Dis. 2001 Mar;2:158-164.
Strømme JH, Rustad P, Steensland H, Theodorsen L, Urdal P. Reference intervals for eight enzymes in blood of adult females and males measured in accordance with the International Federation of Clinical Chemistry reference system at 37 degrees C: part of the Nordic Reference Interval Project. Scand J Clin Lab Invest. 2004 Jul;64:371-384.
Kyriakides T, Angelini C, Schaefer J et al. European Federation of Neurological Societies. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010 Jun 1;17:767-773.
Abraham A, Katzberg HD, Lovblom LE, Bril V. European Federation of Neurological Societies cutoff values significantly reduce creatine kinase sensitivity for diagnosing neuromuscular disorders. Muscle Nerve. 2019 Dec;60:748-752.
Silvestri NJ, Wolfe GI. Asymptomatic/pauci-symptomatic creatine kinase elevations (hyperckemia). Muscle Nerve. 2013 Jun;47:805-815
Prelle A, Tancredi L, Sciacco M et al. Retrospective study of a large population of patients with asymptomatic or minimally symptomatic raised serum creatine kinase levels. J Neurol. 2002 Mar;249:305-311.
Wolf PL. Abnormalities in serum enzymes in skeletal muscle diseases. Am J Clin Pathol. 1991 Mar;95:293-296.
Katzberg HD, Kassardjian CD. Toxic and Endocrine Myopathies. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1815-1828.
Wong ET, Cobb C, Umehara MK et al. Heterogeneity of serum creatine kinase activity among racial and gender groups of the population. Am J Clin Pathol 1983 May;79:582– 586.
Brewster LM, Mairuhu G, Sturk A, van Montfrans GA. Distribution of creatine kinase in the general population: implications for statin therapy. Am Heart J. 2007 Oct;154:655-661.
Scheurbrandt G, Mortier W. Voluntary newborn screening for Duchenne muscular dystrophy: a nationwide pilot program in West Germany. In: Serratrice G, Cros D, Desnuelle C, et al. Editors. Neuromuscular diseases. New York: Raven Press; 1984. p 33–35.
Gilboa N, Swanson JR. Serum creatine phosphokinase in normal newborns. Arch Dis Child. 1976 Apr;51:283-285.
Tiidus PM, Ianuzzo CD. Effects of intensity and duration of muscular exercise on delayed soreness and serum enzyme activities. Med Sci Sports Exerc. 1983 Jun;15:461-465.
Ross JH, Attwood EC, Atkin GE, Villar RN. A study on the effects of severe repetitive exercise on serum myoglobin, creatine kinase, transaminases and lactate dehydrogenase. Q J Med. 1983 Spring;52:268-79.
Lachiewicz PF, Latimer HA. Rhabdomyolysis following total hip arthroplasty. J Bone Joint Surg Br 1991 Jul;73:576-579.
Lenke LG, Bridwell KH, Jaffe AS. Increase in creatine kinase MB isoenzyme levels after spinal surgery. J Spinal Disord. 1994 Feb;7:70-76.
Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008 Jul;21:473-494.
Moon JH, Na JY, Kim JH et al. Neurological and muscular manifestations associated with influenza B infection in children. Pediatr Neurol. 2013 Aug;49:97-101.
Magee H, Goldman RD. Viral myositis in children. Can Fam Physician. 2017 May;63:365-368.
Surges R, Thijs RD, Tan HL, Sander JW. Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms. Nat Rev Neurol. 2009 Sep;5:492-504.
Rosalki SB. Serum enzymes in disease of skeletal muscle. Clin Lab Med. 1989 Dec;9:767-781.
Straub V, Bushby K. The childhood limb-girdle muscular dystrophies. Semin Pediatr Neurol. 2006 Jun;13:104-114.
Tawil R. Facioscapulohumeral muscular dystrophy. Geschwind, H.L. Paulson, and C. Klein, Editors. Handbook of Clinical Neurology, Vol. 148 (3rd series) Neurogenetics, Part II D.H. Elsevier B.V. 2018.p.541-548.
Turner C, Hilton-Jones D. Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol. 2014 Oct;27:599-606.
Logigian EL, Ciafaloni E, Quinn LC et al. Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve. 2007 Apr;35:479-485.
Joshi PR, Zierz S. Muscle Carnitine Palmitoyltransferase II (CPT II) Deficiency: A Conceptual Approach. Molecules. 2020 Apr 13;25:1784.
Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology. 2003 Apr 22;60:1351-1353.
Winkel LP, Hagemans ML, van Doorn PA et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol. 2005 Aug;252:875-884.
Claeys KG. Congenital myopathies: an update. Dev Med Child Neurol. 2020 Mar;62:297-302.
Eom S, Lee HN, Lee S et al. Cause of Death in Children With Mitochondrial Diseases. Pediatr Neurol. 2017 Jan;66:82-88.
Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med. 1989 Oct;18:1068-1084.
Hirano M, Ott BR, Raps EC et al. Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 1992 Nov;42:2082-2087.
Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018 Oct;15:995-1005.
McNeil SM, Woulfe J, Ross C, Tarnopolsky MA. Congenital inflammatory myopathy: a demonstrative case and proposed diagnostic classification. Muscle Nerve. 2002 Feb;25:259-264.
Takagi Y, Yasuhara T, Gomi K. Creatine kinase and its isozymes. Rinsho Byori. 2001 Nov;Suppl 116:52-61.
Venance SL. Approach to the Patient With HyperCKemia. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1803-1814.
Arnold ES, Fischbeck KH. Spinal muscular atrophy. Geschwind, H.L. Paulson, and C. Klein, Editors. Handbook of Clinical Neurology, Vol. 148 (3rd series). Neurogenetics, Part II D.H. Elsevier B.V. 2018.p.591-601.
Zhang L, Zhou H, Peng Q, Jiang W, Qiao W, Wang G. Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. Int J Rheum Dis. 2017 Feb;20:252-260.
Miró O, Pedrol E, Casademont J et al. Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. Semin Arthritis Rheum. 1996 Jun;25(6):421-428.
Ruiz Ginés MA, Calafell Mas MF, Ruiz Ginés JA, Fernández Rodríguez E. Macro-creatincinasa: marcador de enfermedad. Guía práctica para su manejo Macro creatine kinase: illness marker. Practical guide for the management. An Med Interna. 2006 Jun;23:272-275.
Shaibani A, Jabari D, Jabbour M, Arif C, Lee M, Rahbar MH. Diagnostic outcome of muscle biopsy. Muscle Nerve. 2015 May;51:662-668.
Cejas CP, Serra MM, Galvez DFG et al. Muscle MRI in pediatrics: clinical, pathological and genetic correlation. Pediatr Radiol. 2017 May;47:724-735.
Pillen S, Boon A, Van Alfen N. Muscle ultrasound. Masdeu JC, González RG, Editors Handbook of Clinical Neurology. Vol.136 Neuroimaging, Part II. Elsevier B.V. 2016.p.843-853.
D'Adda E, Sciacco M, Fruguglietti ME et al. Follow-up of a large population of asymptomatic/oligosymptomatic hyperckemic subjects. J Neurol. 2006 Nov;253:1399-1403.
Iyadurai SJ, Kissel JT. The Limb-Girdle Muscular Dystrophies and the Dystrophinopathies. Continuum (Minneap Minn). 2016 Dec;22(6,Muscle and Neuromuscular Junction Disorders):1954-1977.
Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020 Aug;66: 101015.
Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010 Feb;110:498-507.
van den Bersselaar LR, Snoeck MMJ, Gubbels M et al. Anaesthesia and neuromuscular disorders: what a neurologist needs to know. Pract Neurol. 2020 Oct 27:practneurol-2020-002633.
